RVL Pharmaceuticals

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, RVL Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 7 completed later-stage tilt upper quartile by trial count

RVL Pharmaceuticals: 7 sponsored US clinical trials, none currently recruiting.

RVL Pharmaceuticals sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 6 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Sclerosis, with 2 trials.

Upper-quartile sponsor footprint

RVL Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

COMPLETED Phase 3

Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

NCT03565887
COMPLETED Phase 3

Study of Safety of RVL-1201 in Treatment of Blepharoptosis

NCT03536949
COMPLETED Phase 3

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS

NCT03319732
COMPLETED Phase 3

Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

NCT02436759
COMPLETED Phase 1

Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

NCT01848041
COMPLETED Phase 3

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

NCT01844232
COMPLETED Phase 3

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

NCT01743651

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 6

Therapeutic Areas

Multiple Sclerosis 2
Acquired Blepharoptosis 1
Spasticity, Muscle 1
Spasticity 1

How the RVL Pharmaceuticals archive is shaped

7 indexed studies, none listed as recruiting (0% open); 7 completed (100%).

Phase mix: 6 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Multiple Sclerosis (2 trials), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

RVL Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

RVL Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share RVL Pharmaceuticals3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
RVL Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

RVL Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this RVL Pharmaceuticals page

7 registered trials is a research-attention snapshot, not an endorsement of RVL Pharmaceuticals or any single study.

  • None of RVL Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Multiple Sclerosis is the condition RVL Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Sclerosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. RVL Pharmaceuticals pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.